Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016
Published Aug 10, 2016
374 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeuti

  
Source:
Document ID
GMDHC8355IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents211
  List of Tables102
  List of Figures121
Introduction131
  Global Markets Direct Report Coverage131
Metastatic Renal Cell Carcinoma Overview141
Therapeutics Development152
  Pipeline Products for Metastatic Renal Cell Carcinoma Overview151
  Pipeline Products for Metastatic Renal Cell Carcinoma Comparative Analysis161
Metastatic Renal Cell Carcinoma Therapeutics under Development by Companies174
Metastatic Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes211
Metastatic Renal Cell Carcinoma Pipeline Products Glance224
  Late Stage Products221
  Clinical Stage Products231
  Early Stage Products241
  Unknown Stage Products251
Metastatic Renal Cell Carcinoma Products under Development by Companies263
Metastatic Renal Cell Carcinoma Products under Investigation by Universities/Institutes291
Metastatic Renal Cell Carcinoma Companies Involved in Therapeutics Development3044
  Acceleron Pharma, Inc.301
  Amgen Inc.311
  Argos Therapeutics, Inc.321
  Astellas Pharma Inc.331
  Bayer AG341
  Bionomics Limited351
  Bionovis SA361
  Bristol-Myers Squibb Company371
  Cellceutix Corporation381
  Celldex Therapeutics, Inc.391
  Cerulean Pharma, Inc.401
  Dr. Reddy's Laboratories Limited411
  EirGenix Inc.421
  Eisai Co., Ltd.431
  Eli Lilly and Company441
  Exelixis, Inc.451
  Gene Techno Science Co., Ltd.461
  Genor BioPharma Co., Ltd.471
  Immune Design Corp.481
  Immunicum AB491
  Incyte Corporation501
  Mabion SA511
  MedImmune, LLC521
  Merck &Co., Inc.531
  Merck KGaA541
  Millennium Pharmaceuticals Inc551
  Mycenax Biotech Inc.561
  NewLink Genetics Corporation571
  Novartis AG581
  Oncobiologics, Inc.591
  Ono Pharmaceutical Co., Ltd.601
  Panacea Biotec Limited611
  Peloton Therapeutics, Inc.621
  Pfizer Inc.631
  Prima BioMed Ltd.641
  Rexahn Pharmaceuticals, Inc.651
  Richter Gedeon Nyrt.661
  Seattle Genetics, Inc.671
  Sevion Therapeutics, Inc.681
  Syndax Pharmaceuticals Inc691
  Taiwan Liposome Company, Ltd.701
  Tocagen Inc.711
  TVAX Biomedical, Inc.721
  Tyrogenex, Inc.731
Metastatic Renal Cell Carcinoma Therapeutics Assessment7422
  Assessment by Monotherapy Products741
  Assessment by Combination Products751
  Assessment by Target768
  Assessment by Mechanism of Action847
  Assessment by Route of Administration912
  Assessment by Molecule Type933
Drug Profiles96257
  AGS-16C3F Drug Profile961
  avelumab Drug Profile975
  bevacizumab biosimilar Drug Profile1022
  bevacizumab biosimilar Drug Profile1041
  bevacizumab biosimilar Drug Profile1051
  bevacizumab biosimilar Drug Profile1061
  bevacizumab biosimilar Drug Profile1071
  bevacizumab biosimilar Drug Profile1081
  bevacizumab biosimilar Drug Profile1091
  bevacizumab biosimilar Drug Profile1101
  bevacizumab biosimilar Drug Profile1111
  bevacizumab biosimilar Drug Profile1121
  bevacizumab biosimilar Drug Profile1131
  BNC-105 Drug Profile1145
  cabozantinib s-malate Drug Profile11918
  capmatinib Drug Profile1373
  CDX-014 Drug Profile1401
  Cellular Immunotherapy for Metastatic Renal Cell Carcinoma Drug Profile1411
  Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma Drug Profile1421
  crizotinib Drug Profile1437
  CRLX-101 Drug Profile15011
  dalantercept Drug Profile1614
  durvalumab Drug Profile16510
  emibetuzumab Drug Profile1752
  entinostat Drug Profile1777
  flucytosine ER + vocimagene amiretrorepvec Drug Profile1847
  G-305 Drug Profile1912
  IMP-321 Drug Profile1934
  INCAGN-1876 Drug Profile1972
  Intuvax Drug Profile1996
  ipilimumab Drug Profile2058
  KM-3174 Drug Profile21311
  lenvatinib mesylate Drug Profile22411
  LY-2510924 Drug Profile2352
  Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma Drug Profile2371
  nivolumab Drug Profile23828
  Orellanine Drug Profile2661
  panobinostat Drug Profile2678
  pazopanib hydrochloride + pembrolizumab Drug Profile2751
  pembrolizumab Drug Profile27631
  PT-2385 Drug Profile3072
  radium Ra 223 dichloride Drug Profile3099
  Recombinant Protein for Oncology Drug Profile3181
  rocapuldencel-T Drug Profile3196
  RX-0201 Drug Profile3254
  sapanisertib Drug Profile3293
  SGN-CD70A Drug Profile3321
  Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma Drug Profile3331
  SNX-5422 Drug Profile3342
  SVN-002 Drug Profile3361
  TLC-388 Drug Profile3372
  trebananib Drug Profile3394
  TVI-Kidney-1 Drug Profile3431
  varlilumab Drug Profile3446
  X-82 Drug Profile3503
Metastatic Renal Cell Carcinoma Dormant Projects3535
Metastatic Renal Cell Carcinoma Discontinued Products3581
Metastatic Renal Cell Carcinoma Product Development Milestones35914
  Featured News &Press Releases3591
    Jul 22, 2016: Immunicum Submits IND Application To The Food And Drug Administration For Approval To Treat Kidney Cancer Patients In The United States In Its Ongoing Phase II-Trial3591
    Jun 13, 2016: Immunicum presents continued improvement in phase I/II survival data for INTUVAX treated renal cancer patients3591
    Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review3601
    Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology3601
    Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting3611
    May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology3621
    Apr 25, 2016: Health Canada Approves OPDIVO (nivolumab) for the treatment of Advanced or Metastatic Renal Cell Carcinoma3631
    Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting3642
    Jan 18, 2016: U.S. FDA Accepts For Priority Review sNDA For Eisai S Anticancer Agent Lenvatinib Seeking Approval For Renal Cell Carcinoma3661
    Jan 11, 2016: Rexahn Pharmaceuticals Archexin Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study3662
    Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis3681
    Nov 23, 2015: FDA approves Opdivo to treat advanced form of kidney cancer3681
    Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium3692
    Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics3711
    Oct 19, 2015: Phase II Trial Results on Novel Anticancer Agent Lenvima in Renal Cell Carcinoma Published in The Lancet Oncology3712
Appendix3732
  Methodology3731
  Coverage3731
  Secondary Research3731
  Primary Research3731
  Expert Panel Validation3731
  Contact Us3731
  Disclaimer3741

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metastatic-Renal-Cell-Carcinoma-Pipeline-Review-H2-2016-2088-16363>
  
APA:
Global Markets Direct - Market Research. (2016). Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metastatic-Renal-Cell-Carcinoma-Pipeline-Review-H2-2016-2088-16363>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.